Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube (Q83566218)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 February 2012

Language	Label	Description	Also known as
English	Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube	scientific article published on 28 February 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

based on heuristic

inferred from title

phase II clinical trial

1 reference

based on heuristic

inferred from title

low-grade serous carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Charles F. Levenback

5

object named as

Charles F Levenback

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Pedro T. Ramirez

6

object named as

Pedro T Ramirez

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

David Gershenson

9

object named as

David M Gershenson

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

7

object named as

Anil K Sood

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Ignacio Romero Noguera

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Charlotte C Sun

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Russell R Broaddus

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Donna Branham

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Robert L Coleman

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

publication date

28 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

125

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

640-645

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Grading ovarian serous carcinoma using a two-tier system

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Low-grade serous ovarian cancer: a unique disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

KIT in ovarian carcinoma: disillusion about a potential therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Expression and mutational analysis of c-kit in ovarian surface epithelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

PDGF BB induces VEGF secretion in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Gastrointestinal stromal tumour.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

The role of imatinib plasma level testing in gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Role of platelet-derived growth factors in physiology and medicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.034

7 January 2021

Identifiers

10.1016/J.YGYNO.2012.02.034

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22387451%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83566218&oldid=2034438986"